The use of propranolol to treat central serous chorioretinopathy: An evaluation by serial OCT

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 2, 2006, Pages 145-149

  Tatham, Andrew ^a   Macfarlane, Adrian ^a  

^a MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; PROPRANOLOL; TRIAMCINOLONE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CASE REPORT; CENTRAL RETINAL THICKNESS; CENTRAL SEROUS RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LASER COAGULATION; METAMORPHOSIS; OCULAR COHERENCE TOMOGRAPHY; RECURRENT DISEASE; REMISSION; RETINA EXAMINATION; RETREATMENT; STEROID THERAPY; THICKNESS; TOMOGRAPHY; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; CHOROID DISEASES; FEMALE; HUMANS; PROPRANOLOL; RECURRENCE; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33646689300     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.145     Document Type: Article

References (18)

1. Yap, E.Y., and Robertson, D.M. The long-term outcome of central serous chorioretinopathy. Arch. Ophthalmol. 114:689-692, 1996.
2. Burumcek, E., Mudun, A., Karacorlu, S., et al. Laser photocoagulation for persistent central serous retinopathy: Results of long-term follow-up. Ophthalmology 104:616-622, 1997.
3. Jonas, J.B., Kamppeter, B.A. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br. J. Ophthalmol. 89:386-387, 2005.
4. Rosenman, R.H., and Friedman, M. Neurogenic factors in pathogenesis of coronary heart disease. Med. Clin. N. Am. 58:269-279, 1974.
5. Ficker, L., Vafadis, G., While, A., et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br. J. Ophthalmol. 72:829-834, 1988.
6. Gelber, G.S., and Schatz, H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am. J. Psychiatr. 144:46-50, 1987.
7. Sun, J., Tan, J., Wang, Z., et al. Effect of catecholamine on central serous chorioretinopathy. J. Huazhong Univ. Sci. Tech. Med. Sci. 23:313-316, 2003.
8. Yoshioka, H. The etiology of central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 95:1181-1195, 1991.
9. Frambach, D.A., Fain, G.L., Farber, D.B., et al. Beta-adrenergic receptors on cultured human retinal pigment epithelium. Invest. Ophth. Vis. Sci. 31:1767-1772, 1990.
10. Sibayan, S.A., Kobuch, K., Spiegel, D., et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: Possible implications on the pathogenesis of central serous chorioretinopathy. Graefes' Arch. Clin. Exp. Ophthalmol. 238:515-519, 2000.
11. Michael, J.C., Pak, J., Pulido, J., et al. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am. J. Ophthalmol. 136:182-185, 2003.
12. Tittl, M.K., Spaide, R.F., Wong, D., et al. Systemic findings associated with central serous chorioretinopathy. Am. J. Ophthalmol. 130:379, 2000.
13. Browning, D.J. Nadolol in the treatment of central serous retinopathy. Am. J. Ophthalmol. 116:770-771, 1993.
14. Chrapek, O., Spackova, K., and Rehak, J. Treatment of central serous chorioretinopathy with beta-blockers. Csk. Slov. Oftalmol. 58:382-386, 2002.
15. Haimovici, R., Koh, S., Gagnon, D.R., et al. Risk factors for central serous chorioretinopathy: A case-control study. Ophthalmology 111:244-249, 2004.
16. Carvalho-Recchia, C.A., Yannuzzi, L.A., Negrao, S., et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 109:1834-1837, 2002.
17. Tyrer, P. Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs 36:773-783, 1998.
18. Elman, M.J., Sugar, J., Fiscella, R., et al. The effect of propranolol versus placebo on resident surgical performance. Trans. Am. Ophthalmol. Soc. 96:283-291, 1998.